On January 4, 2022 Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, reported that the Chief Executive Officer of Boundless Bio, Zachary Hornby, will present at the 40th Annual J.P. Morgan Healthcare Conference which will take place virtually (Press release, Boundless Bio, JAN 4, 2022, View Source [SID1234598125]). Presentation details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Tuesday, January 11, 2022
Time: 2:00 PM – 2:25 PM EST

On January 4, 2022 Median Technologies (Paris:ALMDT) (ALMDT:PA), reported the publication date for its 2021 results (Press release, MEDIAN Technologies, JAN 4, 2022, View Source [SID1234598122]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Publication

Date

2021 results

April 26, 2022*

*Distribution after the close of trading

On January 4, 2022 Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, reported that Gaurav Shah, M.D., Chief Executive Officer, will deliver a company presentation virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 10 at 1:30 p.m. ET (Press release, Rocket Pharmaceuticals, JAN 4, 2022, View Source [SID1234598120]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available under "Events" in the Investors section of the Company’s website a

On January 4, 2022 Novocure (NASDAQ: NVCR) reported it will participate in the 40th Annual J.P. Morgan Virtual Healthcare Conference on January 10 through January 13, 2022 (Press release, NovoCure, JAN 4, 2022, View Source [SID1234598119]). William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 7:30 a.m. EST on January 11, 2022 . Mr. Doyle and Ashley Cordova, Novocure’s Chief Financial Officer, will also participate in one-on-one meetings with investors throughout the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation and all presentation materials can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the event. Novocure has used, and intends to continue to use, its Investor Relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

On January 4, 2022 Arsenal Biosciences, Inc., a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors, reported that members of its senior management team are scheduled to participate in the 40th Annual J.P. Morgan Healthcare Conference being held virtually on Monday, January 10, 2022 (Press release, Arsenal Bio, JAN 4, 2022, View Source [SID1234598117]). The presentation will feature a business overview and update by Ken Drazan, MD, ArsenalBio’s Chairman and Chief Executive Officer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

40th Annual J.P. Morgan Healthcare Conference
Date: Monday, January 10, 2022
Presentation Time: 11:30 a.m. – 12:00 p.m. EST

Please find more details about the J.P. Morgan Healthcare Conference here.